Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Metastatic Mucosal or Acral/Lentiginous Melanoma
NCT00577382Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2007
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in mucosal melanoma (MM) and acral lentiginous melanoma (ALM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: 2-month Progression-free Survival Rate. Started Aug 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
mucosal melanoma (MM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT00577382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577382.